- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Purpose Bitcoin ETF
Silver47 Exploration
Syntheia
CI Galaxy Bitcoin ETF
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
CURE Pharmaceutical Gets Patents for Cannabis Extraction
CURE Pharmaceutical announced the acquisition of two new patents for the extraction and purification of cannabis plant material.
CURE Pharmaceutical (OTC:CURR) announced the acquisition of two new patents for the extraction and purification of cannabis plant material.
As quoted in the press release:
“The endocannabinoid system is a powerful pathway to treat many diseases and illness, and these patents will allow us to implement accurate and optimal dosing for treatments that would target this system,” said Rob Davidson, CEO of CURE Pharmaceutical. “We have only seen a glimpse of the potential of cannabinoids, which we are unlocking with our proprietary delivery technology.”
The patents will be key to reproducing and commercializing the research findings from the Technion – Israel Institute of Technology, a public research university in Haifa, Israel where CURE is sponsoring research. The current research at Technion is testing fractionated molecular components from the cannabis plant against various cancer types in vitro and in preclinical models.
The two issued U.S. patents No. 9,044,390 and 9,186,386 cover the extraction and fractioning of bioactive cannabinoid molecules from the cannabis plant, allowing the integration of these molecules into a dosage form, such as CUREfilm™, the most advanced oral thin film on the market today.
Click here to read the full press release.
Source: globenewswire.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.